

Grand Rounds

Tuesday, January 28, 12:00pm

Smilow Auditorium, 55 Park Street

Join us in person for lunch

[Zoom Access](#)

THE EVOLUTION OF ANTIBODY- DRUG CONJUGATES IN ONCOLOGY: HAVE WE FOUND OUR “MAGIC BULLET”?

Ian Krop, MD, PhD

Associate Cancer Director for Clinical Research

Needs:

Antibody-drug conjugates are a relatively new, unique, and rapidly evolving class of cancer therapeutics. There is thus an important clinical need for:

- Understanding the optimal clinical use of these agents
- Understanding the optimal management of their toxicities
- Understanding potential mechanisms of resistance to these agents and approaches being explored to overcome these resistance mechanisms.

Objectives:

- Understand the clinical applications of antibody drug conjugates in breast cancer
- Know the potential toxicities of ADCs and appropriate management
- Learn the potential mechanisms of resistance to ADCs and possible approaches to overcome these mechanisms



Ian Krop, MD, PhD, is a professor of internal medicine, specializing in medical oncology, with expertise in the management of breast cancer. Among his leadership roles at Yale Cancer Center, Dr. Krop serves as Associate Cancer Center Director for Clinical Research, Director of the Yale Cancer Center Clinical Trials Office, and Chief Clinical Research Officer.

Dr. Krop's research interests include the treatment of HER2-positive breast cancer through the investigation of various therapies, evaluation of genomic tools, and analysis of patient-reported outcomes. He participates in clinical trials that examine the role of neoadjuvant therapies in cancer treatment and ways to manage of spread of cancer to the brain. His work also examines patient-reported outcomes in breast cancer clinical trials and the correlation between the PIK3CA mutation and breast cancer outcomes.

Dr. Krop's research team has been awarded with grants from the National Cancer Institute, Susan G. Komen Breast Cancer Foundation, the Breast Cancer Research Foundation, and the American Association for Cancer Research. His work has significantly influenced patient care and medical education, leading to an improved understanding of resistance to HER2-directed therapies, the identification of potential tumor suppressors, and strategies to overcome residual disease in HER2-positive breast cancer.



Continuing Medical Education
Yale CME